Endothelial barrier dysfunction and oxidative stress: Roles for nitric oxide?

被引:61
作者
McQuaid, KE [1 ]
Keenan, AK [1 ]
机构
[1] NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND
基金
英国惠康基金;
关键词
D O I
10.1113/expphysiol.1997.sp004032
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Endothelial dysfunction has an important role to play in the pathophysiology of human vascular disease. The maintenance of barrier function is critical to the role of vascular endothelium in cardiovascular haemostasis and this function can be compromised by inflammatory mediators, cytokines or oxidants. Under conditions of oxidative stress a variety of reactive oxygen species (ROS) may be generated, which increase the permeability of the endothelial monolayer to fluid, macromolecules and inflammatory cells. The endothelium-derived nitric oxide radical (NO), whose physiological actions include effects on vascular smooth muscle, is normally inactivated by the superoxide radical anion. While large amounts of NO have cytotoxic potential, it is now becoming clear that combinations of NO with ROS can produce either cytotoxic or cytoprotective effects, depending on the relative amounts of each which are present in the target cell or its environment at a particular time. The contribution of NO to oxidant-mediated endothelial barrier dysfunction can be assessed in vitro in endothelial monolayers grown on porous membrane supports. In this model, using hydrogen peroxide (H2O2) as the oxidant, H2O2-induced losses of barrier function can be enhanced or partially offset by NO donor drugs, depending on the concentration of NO donor used. Furthermore, the injurious or cytoprotective effects of these agents appear to be determined by the quantity of NO generated. Since NO is administered clinically by inhalation in conditions such as pulmonary hypertension or the adult respiratory distress syndrome, which are themselves associated with generation of ROS, it is likely that low concentrations of NO may protect the pulmonary vascular endothelium while high concentrations might be expected to combine with ROS to yield intermediates capable of causing further endothelial injury or loss of barrrier function.
引用
收藏
页码:369 / 376
页数:8
相关论文
共 30 条
[1]   BETA(2)-ADRENOCEPTORS MEDIATE A REDUCTION IN ENDOTHELIAL PERMEABILITY IN-VITRO [J].
ALLEN, MJ ;
COLEMAN, RA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 274 (1-3) :7-15
[2]   INACTIVATION OF GLUTATHIONE-PEROXIDASE BY NITRIC-OXIDE - IMPLICATION FOR CYTOTOXICITY [J].
ASAHI, M ;
FUJII, J ;
SUZUKI, K ;
SEO, HG ;
KUZUYA, T ;
HORI, M ;
TADA, M ;
FUJII, S ;
TANIGUCHI, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (36) :21035-21039
[3]   INHIBITION OF HUMAN GLUTATHIONE-REDUCTASE BY S-NITROSOGLUTATHIONE [J].
BECKER, K ;
GUI, M ;
SCHIRMER, RH .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 234 (02) :472-478
[4]   APPARENT HYDROXYL RADICAL PRODUCTION BY PEROXYNITRITE - IMPLICATIONS FOR ENDOTHELIAL INJURY FROM NITRIC-OXIDE AND SUPEROXIDE [J].
BECKMAN, JS ;
BECKMAN, TW ;
CHEN, J ;
MARSHALL, PA ;
FREEMAN, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (04) :1620-1624
[5]   NITRIC-OXIDE AS A MEDIATOR OF OXIDANT LUNG INJURY DUE TO PARAQUAT [J].
BERISHA, HI ;
PAKBAZ, H ;
ABSOOD, A ;
SAID, SI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (16) :7445-7449
[6]   ARTERIAL ENDOTHELIAL BARRIER DYSFUNCTION - ACTIONS OF HOMOCYSTEINE AND THE HYPOXANTHINE-XANTHINE OXIDASE FREE-RADICAL GENERATING-SYSTEM [J].
BERMAN, RS ;
MARTIN, W .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 108 (04) :920-926
[7]   NITRIC-OXIDE REGULATES MITOCHONDRIAL RESPIRATION AND CELL FUNCTIONS BY INHIBITING CYTOCHROME-OXIDASE [J].
BROWN, GC .
FEBS LETTERS, 1995, 369 (2-3) :136-139
[8]   MODULATION OF BARRIER FUNCTION OF BOVINE AORTIC AND PULMONARY-ARTERY ENDOTHELIAL-CELLS - DISSOCIATION FROM CYTOSOLIC CALCIUM CONTENT [J].
BUCHAN, KW ;
MARTIN, W .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 107 (04) :932-938
[9]   MODULATION OF HUMAN ENDOTHELIAL-CELL PERMEABILITY BY COMBINATIONS OF THE CYTOKINES INTERLEUKIN-1 ALPHA/BETA, TUMOR-NECROSIS-FACTOR-ALPHA AND INTERFERON-GAMMA [J].
BURKEGAFFNEY, A ;
KEENAN, AK .
IMMUNOPHARMACOLOGY, 1993, 25 (01) :1-9
[10]   CLINICAL BIOLOGY OF NITRIC-OXIDE [J].
DAVIES, MG ;
FULTON, GJ ;
HAGEN, PO .
BRITISH JOURNAL OF SURGERY, 1995, 82 (12) :1598-1610